A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phase 1 study of DSP-2033 (Alvocidib) in combination
with cytarabine/mitoxantrone (ACM regimen) or cytarabine/daunorubicin (A+7+3 regimen) in
patients with acute myeloid leukemia (AML).